What VALSARTAN BASICS Treats: Main Uses and Benefits

Quick Facts: Valsartan
Therapeutic Areas
* Assists in the management of high blood pressure (hypertension).
* Supports the treatment of heart failure.
* May be used in clinically stable patients following a heart attack who have left ventricular dysfunction or failure.

---

Valsartan is a prescription medication utilized in several core therapeutic areas to support cardiovascular health. The medication is used for the management of high blood pressure, also known as hypertension, in adults and pediatric patients six years of age and older. By assisting in the maintenance of healthy blood pressure levels, this treatment contributes to reducing the risk of cardiovascular events, such as strokes and heart attacks.

Additionally, Valsartan provides support for individuals with heart failure. For these patients, the treatment is indicated to assist in reducing the need for hospitalization related to heart failure symptoms.

Following a heart attack (myocardial infarction), Valsartan may be used in clinically stable patients who experience left ventricular failure or left ventricular dysfunction. This use serves to provide support for cardiovascular well-being in the post-infarction period. Always consult the full prescribing information for specific approved uses and patient populations.

Valsartan eligibility is defined by strict regulatory criteria across age, reproductive status, and existing medical conditions, establishing who is permitted, restricted, or prohibited from using the medicine.

Adults are eligible for all approved uses. Pediatric patients are restricted to those 6 years of age and older for the treatment of hypertension only. Use is not recommended for children under six, nor for children with heart failure or post-myocardial infarction.

Valsartan is formally contraindicated and must not be used in several populations, most notably pregnant women due to the significant risk of fetal harm. It is also prohibited for patients with a known hypersensitivity to the drug. A key restriction is the prohibition of use in patients with diabetes mellitus who are concurrently taking the medicine Aliskiren, or in patients with certain renal impairments taking Aliskiren. Furthermore, use is prohibited in patients with severe hepatic impairment or cholestasis.

Use is not recommended for women who are breastfeeding or for patients with primary hyperaldosteronism. Special caution and monitoring are required for patients with severe renal impairment and for those with uncorrected volume or salt depletion, as defined by official labeling.

Interactions with other medicines and products

Official regulatory information for Valsartan focuses on pharmacodynamic (PD) risks of dual therapy and pharmacokinetic (PK) exposure modification.

---

Documented Interaction Patterns

Interaction Type	Interacting Substance(s)	Official Description of Outcome
Contraindicated Combination	Aliskiren	Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment due to increased risk of hypotension, hyperkalemia, and impaired renal function (dual RAAS blockade).
Pharmacodynamic Risk	Potassium-sparing diuretics, Potassium supplements, Salt substitutes containing potassium	Co-administration may result in hyperkalemia (increased serum potassium) due to additive effects.
Pharmacokinetic Exposure	OATP1B1 and OATP1B3 Inhibitors	Valsartan is a substrate for these hepatic uptake transporters. Inhibition is expected to increase the systemic exposure (AUC and Cmax) of Valsartan.
Exposure Modification	Lithium	Co-administration may lead to increases in serum lithium concentrations and the risk of lithium toxicity.
Drug–Food Interaction	Food	Administration with food results in a reduction in absorption, leading to a decrease in systemic exposure (AUC and Cmax) of Valsartan.

---

Restrictions and Regulatory Notes

Pharmacokinetic interactions mediated by CYP enzymes are considered unlikely to be clinically significant. No mandatory temporal separation rules are explicitly documented in the primary regulatory labels for the monotherapy product. The combination with Aliskiren is specifically restricted to patients with pre-existing renal impairment or diabetes.

Valsartan functions as a highly selective competitive antagonist of the angiotensin II type 1 ( AT1) receptor. It primarily targets AT1 receptors found on vascular smooth muscle cells, myocardial tissue, adrenal glands, and in the renal system.

Upon systemic absorption, Valsartan binds to the AT1 receptor, exhibiting a pKi in the nanomolar range, thereby preventing the binding and subsequent activation of the endogenous ligand, angiotensin II ( Ang II). This blockade inhibits the Ang II-mediated signal transduction cascade.

Intracellularly, Ang II binding typically activates Gq protein-coupled pathways, leading to the activation of phospholipase C ( PLC). PLC subsequently hydrolyzes phosphatidylinositol 4,5-bisphosphate ( PIP2) into inositol trisphosphate ( IP3) and diacylglycerol ( DAG). IP3 triggers the release of intracellular calcium ( Ca^2+) stores, while DAG activates protein kinase C ( PKC). These combined intracellular events mediate Ang II's effects, including vasoconstriction and aldosterone release.

Valsartan’s AT1 antagonism abolishes this cascade, resulting in decreased intracellular Ca^2+ mobilization in vascular smooth muscle cells. The systemic physiological consequence of this AT1 receptor blockade is a reduction in peripheral vascular resistance due to the inhibition of Ang II-induced vasoconstriction and a reduction in aldosterone secretion.

How to Use Valsartan: Official Administration Guidelines

Valsartan is administered via the oral route, available primarily as a tablet in strengths of 40 mg, 80 mg, 160 mg, and 320 mg, and also as an oral solution or suspension. The medication may be taken with or without food but should be taken at the same time each day for consistency.

---

Dosing Frequency and Schedules

The required dosing frequency is specific to the condition being managed:

• Hypertension (High Blood Pressure): The dosing regimen is typically once daily. The starting dose is usually 80 mg or 160 mg, with the labeled maximum daily dose being 320 mg.

• Heart Failure and Post-Myocardial Infarction (Post-MI): The regimen is twice daily (BID), with treatment initiated at a lower starting dose. For heart failure, this is commonly 40 mg BID, and for post-MI, as low as 20 mg BID, initiated as early as 12 hours after the event. Doses are then gradually increased over time to reach the full maintenance dose, following labeled titration schedules.

---

Population-Specific Administration

Official instructions include specific limitations for certain groups. For patients with mild-to-moderate hepatic impairment (liver dysfunction) without cholestasis, the total daily dose should not exceed 80 mg. For pediatric patients aged 6 to 16 years being treated for hypertension, dosing is weight-based, starting at 1.3 mg/kg once daily, up to a maximum of 160 mg daily. If a dose is missed, it is advised to take the next dose at the regular time and not to take a double dose to compensate. The oral suspension requires shaking well before each use.

Recent Clinical Evidence: Valsartan

Clinical trials have established the compound Valsartan as an Angiotensin II Receptor Blocker (ARB), primarily focusing on its role in managing cardiovascular conditions. The key areas of research and approved indications include hypertension (high blood pressure), heart failure, and post-myocardial infarction (heart attack) care.

---

Pivotal Trial Findings

• Hypertension: Large-scale studies demonstrated Valsartan's efficacy in lowering both systolic and diastolic blood pressure. A reduction in blood pressure is associated with a lower risk of fatal and nonfatal cardiovascular events, particularly strokes and myocardial infarctions.
• Heart Failure (HF): Trials involving patients with NYHA class II–IV heart failure observed that the use of Valsartan reduced the risk of hospitalization for heart failure.
• Post-Myocardial Infarction (MI): Research supports the use of the compound in clinically stable patients with left ventricular failure or dysfunction following an MI to reduce the risk of cardiovascular mortality.

---

Combination Therapy and Future Research

Valsartan is a key component in the combination therapy Sacubitril/Valsartan, a dual-acting agent often used in heart failure with reduced ejection fraction (HFrEF). Pivotal trials for this combination suggested a greater reduction in cardiovascular mortality and heart failure hospitalization compared to some conventional treatments.

Ongoing studies continue to explore the compound's potential effects on renal outcomes, such as reductions in urinary albumin and protein excretion in patients with co-existing conditions like type 2 diabetes and chronic kidney disease.

Key Studies & References Valsartan in acute myocardial infarction trial (VALIANT): baseline characteristics in context

Common questions about VALSARTAN BASICS (FAQ)

---

Q: How long does it take for Valsartan to start lowering blood pressure?

Official product information indicates that the blood pressure-lowering effect of Valsartan is usually noticeable within two weeks of starting treatment. The maximal effect, meaning the fullest intended reduction in blood pressure, is typically achieved after approximately four weeks of consistent use.

---

Q: What is the difference between Valsartan and the combination pill Sacubitril/Valsartan?

Valsartan alone belongs to a class of drugs called Angiotensin II Receptor Blockers (ARBs). The combination pill pairs Valsartan with a different active ingredient called Sacubitril, which is a Neprilysin Inhibitor. This combination gives the medicine a dual mechanism of action, often used for specific types of heart failure.

---

Q: Can Valsartan cause weight gain or loss?

According to regulatory safety reports, changes in weight are not listed among the most common adverse reactions seen in clinical trials. While weight loss is reported in some post-marketing experiences, it is not considered a typical or minor side effect of this medicine. Unexpected or concerning changes in weight should be discussed with a healthcare provider.

---

Q: Can men or women take Valsartan if they are trying to conceive?

Valsartan is contraindicated (must not be used) in pregnant women due to the serious risk of harm to the fetus. Women who are planning pregnancy or become pregnant should consult with a healthcare professional, as immediate discontinuation of the medicine is typically required. Official documents generally do not provide specific guidance on effects related to male fertility.

---

Q: Can Valsartan interact with any other medications or supplements?

Official documents warn of specific, important interactions with certain medicines like Aliskiren and products containing potassium. While general supplements are not listed individually, it is important that patients report all concurrent prescription medicines and supplements to a healthcare provider. A healthcare provider can review this information to help manage potential interactions.

---

Q: Does Valsartan have a Boxed Warning? If so, what is it for?

Yes, Valsartan carries a strong regulatory warning known as a Boxed Warning, which highlights a serious safety concern. This warning is for Fetal Toxicity, meaning the medication can cause injury or death to a developing fetus. Regulatory information states that the medicine should be discontinued immediately upon detection of pregnancy.

---

Q: What is the recommended starting dose for Valsartan when treating heart failure?

According to official dosage information, the initial dose for heart failure is usually low and taken twice daily. The initial dose is part of a regimen where the amount is gradually adjusted over time under the supervision of a healthcare professional.

Valsartan tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C (86 F). The medication must be stored in a closed container, away from excess heat and moisture, and out of the reach of children.

Storage Classification	Required Temperature	Child Safety
Controlled Room Temperature	20 C – 25 C	Keep out of reach of children

For disposal, the officially recommended method is to use a drug take-back program or an authorized collection site. If a take-back option is unavailable, the tablets can be discarded in the household trash by mixing them with an undesirable substance (e.g., used coffee grounds or dirt) and placing the mixture into a sealed container. The medicine is not on the list of products authorized for flushing down the toilet.